Despite these controversies, adiponectin is gaining attention as a potential therapeutic target for diverse CNS disorders, such as stroke, Alzheimer's disease, anxiety, and depression. Here, ADIPOQ is linked to early-onset autosomal dominant Alzheimer disease.